The heterogenous landscape of EGFR Del19 mutation subtype: not all are the same for osimertinib
Boris Duchemann,Emmanuelle Fabre,Jordi Remon
DOI: https://doi.org/10.21037/tlcr-24-30
2024-04-26
Translational Lung Cancer Research
Abstract:Boris Duchemann 1,2 , Emmanuelle Fabre 3 , Jordi Remon 4 1 Medical and Thoracic Oncology, HUPSSD Avicenne Hospital APHP, Bobigny, France; 2 INSERM UMR1272, Paris 13, the University Sorbonne Paris Nord, Bobigny, France; 3 Biochemistry Department AP-HP, HUPSSD Avicenne Hospital APHP, Bobigny, France; 4 Department of Cancer Medicine, Paris-Saclay University, Gustave Roussy, Villejuif, France Comment on: Grant MJ, Aredo JV, Starrett JH, et al . Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations. Clin Cancer Res 2023;29:2123-30. Submitted Jan 29, 2024. Accepted for publication Mar 28, 2024. Published online Apr 24, 2024. doi: 10.21037/tlcr-24-30 The discovery of druggable genomic alterations represents a significant advancement in the management of non-small cell lung cancer (NSCLC). The presentation of these alterations, varies from mutation to translocation or gene amplifications, thereby demonstrating a high degree of heterogeneity. Notably, different subtype of oncogene driven alterations may correlate with distinct clinical characteristics and actionability. For instance, in the case of BRAF mutations, only class I mutations are druggable with anti-BRAF and anti-MEK inhibitors, while class II and III of BRAF-mutant tumors are associated with higher risk of brain metastases and less favorable outcome (1). Similarly, KRAS mutant NSCLCs exhibit different subtypes based on smoking pattern, and personalized approvals exists only for KRAS G12C subtype (2). Sensitizing common epidermal growth factor receptor ( EGFR ) mutations (deletion in exon 19, Del19, and point mutations in exon 21, L858R) are among the most common targetable driver mutations in patients with NSCLC (3), occurring in up to 10% of NSCLCs in Western-population (4). These mutations confer sensitivity to EGFR tyrosine kinase inhibitors (TKIs), with osimertinib, a third-generation EGFR TKI, emerging as the preferred treatment option in the metastatic setting. This preference is based on a significant prolongation in progression-free survival (PFS) and overall survival (OS) when compared with first-generation EGFR TKIs. Additionally, osimertinib has become the standard adjuvant treatment among patients with completely resected early-stage NSCLC harboring common EGFR mutations (5,6). However, data reported in clinical trials do not consider the subtypes of common EGFR-mutations, which could potentially impact in the clinical efficacy. It is suggested that EGFR-mutant tumors should be classified more based on the structural changes rather than exon position, as it may influence the sensitivity to EGFR TKI (7). There are more than fifty EGFR Del19 mutations described, and their prognostic and predictive role are poorly understood. In preclinical models, these EGFR Del19 variants other than EA746-A750 have reported a different degree of activity to different EGFR TKI with lower efficacy to the first-generation TKI erlotinib, but also for osimertinib, while afatinib, a second-generation EGFR TKI reported clinical activity (8,9). These observations may provide an explanation for the divergent outcomes observed in daily practice when all common EGFR -mutant NSCLCs are uniformly treated with osimertinib. It underscores the importance of considering structural subclassification and others factors to refine prognostic and treatment strategies in this population. In the article accompanying this editorial, Grant et al. reported that that EGFR Del19 made up 45% of EGFR mutations (10). The E746_A750del was the most common EGFR Del19 (27.3% of all EGFR mutations), followed by L747_P753>S (2.8%), and the L747_A750delinsP represented 1.8% of all EGFR Del19 mutations. The authors, retrospectively assessed the clinical activity of osimertinib in 200 patients with NSCLC harboring EGFR Del19 from six institutions. This cohort included 122 patients with tumors harboring E746_A750del (n=86), 36 tumors harboring the L747_A750delinsP (n=36), and 78 patients with tumors harboring other uncommon Del19. A non-significantly higher proportion of patients with tumors harboring L747_A750delinsP received osimertinib in the first-line setting vs. those with E746_A750del (81% vs. 64%, P=0.07), and in both cohorts up to one-third of patients were females and current or former smokers. In the first-line setting, there was a 48% increased risk of progression with osimertinib for patients with tumors harboring L747_A750delinsP compared to those with E746_A750del [median PFS: 11.7 vs. 21.3 months, adjusted hazard ratio (HR) =0.52; 95% confidence interval (CI): 0.28–0.98; P=0.043], with a 1-year PFS rate of 48% and 79% -Abstract Truncated-
oncology,respiratory system